Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [1]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- RA0186 - Provider product page
- Provider
- Oursmab
- Product name
- Enoticumab (Biosimilar Reference Antibody) (DLL4)
- Antibody type
- Monoclonal
- Description
- Enoticumab is an investigational, humanized immunoglobulin G1 kappa (IgG1¦Ê) monoclonal antibody developed as an anti-angiogenic therapy for solid tumors. It functions as a selective inhibitor of the Notch signaling pathway by specifically targeting the Delta-like ligand 4 (DLL4). By binding to DLL4, enoticumab blocks its interaction with the Notch receptors (primarily Notch1 and Notch4) on neighboring endothelial cells. This blockade inhibits the Notch signaling cascade, which is crucial for proper vascular development and tumor angiogenesis. In preclinical models, such as ovarian cancer xenografts, this mechanism has translated into significant anti-tumor activity and effective suppression of tumor growth.
- Reactivity
- Human
- Isotype
- IgG
- Vial size
- 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
- Concentration
- Bottled at the concentration indicated on the vial.
- Storage
- Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
No comments: Submit comment
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- Enoticumab (Biosimilar Reference Antibody) (DLL4)-RA0186-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- ELISA plate pre-coated Antigen protein, can bind Enoticumab (Biosimilar Reference Antibody) (DLL4)-RA0186 in a linear range of 3.91-125 ng/mL.
